Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) EBITDA (2016 - 2025)

Prestige Consumer Healthcare (PBH) has 16 years of EBITDA data on record, last reported at $48.1 million in Q4 2025.

  • For Q4 2025, EBITDA rose 1.39% year-over-year to $48.1 million; the TTM value through Dec 2025 reached $196.4 million, down 2.9%, while the annual FY2025 figure was $211.4 million, 2.44% up from the prior year.
  • EBITDA reached $48.1 million in Q4 2025 per PBH's latest filing, up from $42.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $60.5 million in Q4 2023 and bottomed at -$242.6 million in Q1 2023.
  • Average EBITDA over 5 years is $35.3 million, with a median of $50.6 million recorded in 2021.
  • Peak YoY movement for EBITDA: crashed 531.25% in 2023, then skyrocketed 117.93% in 2024.
  • A 5-year view of EBITDA shows it stood at $51.4 million in 2021, then rose by 14.57% to $58.9 million in 2022, then increased by 2.7% to $60.5 million in 2023, then fell by 21.66% to $47.4 million in 2024, then rose by 1.39% to $48.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $48.1 million in Q4 2025, $42.9 million in Q3 2025, and $52.9 million in Q2 2025.